{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Treatment emergent adverse events observed during outcome measure time frame. A Treatment Emergent Adverse Event was defined as an AE occurring after the start of IMP administration.","groups":[{"description":"OPB-51602: 1, 2, 3, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle\n\nOPB-51602: once daily during the treatment period","id":"OG000","title":"OPB-51602"}],"paramType":"NUMBER","populationDescription":"Safety population No statistical analysis provided for Subjects With Treatment Emergent Adverse Events.","reportingStatus":"POSTED","timeFrame":"From first study medication to on Day 31 (after repeated 28 days medication from Day 4 to 31)","title":"Subjects With Treatment Emergent Adverse Events","type":"PRIMARY","unitOfMeasure":"participants"}